In April 2017, AIFA (Agenzia Italiana del Farmaco, Italian Medicines Agency) released a new algorithm to assess and evaluate the level of innovativeness of new drugs aimed to get reimbursement by the SSN (Sistema Sanitario Nazionale, National Health System) through the EUR 1 billion fund made available by the Italian…
NOTE: this post is the second of three assessing $ESRX’s new INSIDERX programme. Be sure to read the first posting in this series. $ESRX’s INSIDERX programme made waves when it was announced as a means for the uninsured to gain similar levels of discounting to those achieved by the PBM…
Thomas Paine wrote in his presciently titled piece, The American Crisis, that ‘these are the times that try men’s souls’. Although chances are low that he had value frameworks in mind, Mr. Paine likely understood that, in a country that so cherishes liberty, equality may from time to ti me…
The federal political pressure on drug pricing may have stalled on Washington gridlock, but as we previously covered here at CBPartners, it is driving real change at the state level. State lawmakers are better positioned to develop laws that regulate pharmaceutical stakeholders, given the more manageable scope of state markets,…
The past 18 months have ushered in momentous healthcare policy events – spanning from anxiety about the ACA’s repeal and its resulting vacuum of coverage to value frameworks and demands for policy action on price controls for companies that inflate pricing without apparent innovation. Products in the crosshairs of disenchantment…
NOTE: this post is the first of three assessing $ESRX’s new INSIDERX programme. To read more, click here. According to the Kaiser Family Foundation, 28.9 million people in the USA under the age of 65 lack health insurance coverage. The underinsured, who represent individuals who have insurance, but suffer from…
One might describe the typical pharmaceutical pipeline as a cash sinkhole. A primordial factor is the high attrition rate of candidates through the development programme. But before the plug is officially pulled at the end of an unsuccessful phase, weak interim data can portend future failure, or the product may…
The Chinese National Reimbursement Drug List (NRDL), which, before February, was last updated in 2009, has received a much-needed modernisation. On February 21, 2017, the NRDL was updated, and then officially published two days later. The new version of the NRDL can be found here. FIGURE 1. Formulary Structure of…
UPDATE – December 2017: After initially refusing to reimburse EXONDYS 51™, ANTHEM and EMBLEMHEALTH reversed their decisions in late 2017. While EMBLEM opted for a somewhat restrictive policy requiring patients to complete at least 300m in the 6-MWT, ANTHEM decided to cover patients as long as they are ambulatory. In their…
It is no secret that the failure of Bristol-Myers Squibb’s ($BMY) OPDIVO™ to meet PFS endpoints in CheckMate-026 was a major set-back, leading to a dramatic reduction in market cap (~20%) in its aftermath. BMY undoubtedly has a high-potential pipeline gained mostly through its string-of-pearls acquisition and partnership strategy over…